AREDS2tyyppisiä

AREDS2tyyppisiä refers to a specific formulation of nutrient supplements designed to address age-related eye conditions, particularly age-related macular degeneration (AMD). The original Age-Related Eye Disease Study (AREDS) identified a combination of vitamins and minerals that could slow the progression of moderate to advanced AMD. The AREDS2 study, a subsequent clinical trial, refined this formula based on new research.

The AREDS2 formula consists of specific dosages of Vitamin C, Vitamin E, Lutein, Zeaxanthin, Zinc, and Copper. Lutein and Zeaxanthin are carotenoids found in the macula of the eye and are believed to play a role in protecting the retina from harmful blue light. Zinc is important for retinal function, and copper is included to prevent copper deficiency, which can occur with high zinc intake. The AREDS2 formulation notably removed beta-carotene, which had been linked to an increased risk of lung cancer in smokers, and adjusted the amounts of Zinc and Copper compared to the original AREDS formula.

These supplements are generally recommended for individuals diagnosed with intermediate AMD in one or both eyes, or those with advanced AMD in one eye and no AMD in the other. They are not intended to prevent AMD in healthy individuals or to cure existing AMD. The decision to use AREDS2-type supplements should always be made in consultation with an eye care professional who can assess individual risk factors and provide personalized recommendations. The effectiveness of the supplements can vary between individuals, and they are part of a comprehensive eye care management plan.